The aggregation of hypertrophic macrophages constitutes the basis of all granulomatous diseases, such as tuberculosis or sarcoidosis, and is decisive for disease pathogenesis. However, macrophage-intrinsic pathways driving granuloma initiation and maintenance remain elusive. We found that activation of the metabolic checkpoint kinase mTORC1 in macrophages by deletion of the gene encoding tuberous sclerosis 2 (Tsc2) was sufficient to induce hypertrophy and proliferation, resulting in excessive granuloma formation in vivo. TSC2-deficient macrophages formed mTORC1-dependent granulomatous structures in vitro and showed constitutive proliferation that was mediated by the neo-expression of cyclin-dependent kinase 4 (CDK4). Moreover, mTORC1 promoted metabolic reprogramming via CDK4 toward increased glycolysis while simultaneously inhibiting NF-B signaling and apoptosis. Inhibition of mTORC1 induced apoptosis and completely resolved granulomas in myeloid TSC2-deficient mice. In human sarcoidosis patients, mTORC1 activation, macrophage proliferation and glycolysis were identified as hallmarks that correlated with clinical disease progression. Collectively, TSC2 maintains macrophage quiescence and prevents mTORC1dependent granulomatous disease with clinical implications for sarcoidosis.
Granulomas are compact aggregates of mature macrophages with an increased cytoplasmic size whose membranes become interlaced, leading them to be called epithelioid cells 1 . They are usually formed and maintained in response to the continuous presence of either infectious stimuli, such as bacteria, fungi, protozoa, trematodes and viruses, or in response to non-infectious foreign-body particles. Tuberculosis and schistosomiasis are prime examples of infectious granulomatous diseases, whereas non-infectious granuloma formation is observed in sarcoidosis, Crohn's disease and primary biliary cirrhosis, as well as in neoplasias [2] [3] [4] [5] [6] . Sarcoidosis is an enigmatic granulomatous disease of unknown etiology that most commonly affects the lung, lymph nodes, skin and liver 5 . The onset is gradual from an asymptomatic state to a progressive disease that persists in about one-third of patients and can become life threatening 5, 7 . Molecular signals or pathways that control disease progression are largely undefined 8, 9 . When treatment is required, corticosteroids are usually recommended, but they are associated with severe side effects 7 . As a result of the unknown etiology, there are currently no therapeutic approaches targeting the pathogenetic mechanisms.
Given the fact that granulomas have such a major clinical role in disease pathologies, the morphological properties of granuloma formation have been extensively studied. Generally, the principal and initiating element of a granuloma is the macrophage; for example, alveolar macrophages induce granuloma formation after mycobacterial infection in the lung 2, 10, 11 . However, many other cell types are also found later on in mature granulomas, such as neutrophils, dendritic cells, B and T cells, NK cells, and fibroblasts 6, 11, 12 . These cells mostly surround the basic macrophage core to form a highly organized granulomatous structure. However, severe combined immunodeficiency (SCID) mice are still able to form granulomas after mycobacteria infection, indicating that adaptive immunity has a non-essential role in granuloma initiation 10 . Thus, the adaptive immune system contributes more to granuloma organization and protection to limit dissemination of the infection and injury for the host 2, 13, 14 . Similarly, although factors such as tumor necrosis factor, interferon-γ, interleukin (IL)-12, IL-10, the chemokine CCL2, heme oxygenase 1 and matrix metalloproteinase 9 regulate granuloma organization and pathogen susceptibility in infectious granulomatous diseases, initial A r t i c l e s granuloma formation occurs independently of these signals 10, 15, 16 . Thus, the fundamental molecular pathways underlying macrophage transformation to hypertrophic epithelioid cells that aggregate, initiate and maintain macrophage granulomas are still unknown.
The mechanistic target of rapamycin (mTOR) signaling pathway senses and integrates a range of environmental signals to regulate cellular metabolism and cell growth in many cell types and has been implicated in an increasing number of pathological conditions 17 . TSC2 is a tumor suppressor that forms a heterodimeric complex with TSC1 and negatively regulates mTOR complex 1 (mTORC1) 18 . The mTOR pathway, as an energy and nutritional sensor, is exquisitely suited to regulate processes such as glycolysis or mitochondrial metabolism to influence effector responses 19, 20 . Activation of mTORC1 regulates inflammatory immune responses in innate immune cells, such as monocytes, macrophages and dendritic cells 21 . Genetic manipulation of the mTOR pathway in mice alters macrophage polarization and the production of inflammatory and immunomodulatory cytokines [22] [23] [24] . However, it is not known whether the mTORC1 pathway in macrophages has additional functions. We found that activation of mTORC1 by deletion of Tsc2 in macrophages was sufficient to initiate and maintain granulomas. Molecularly, we found that mTORC1 inhibited apoptosis and induced macrophage proliferation by inducing the expression of CDK4 and metabolic reprogramming. These mechanistic features are also associated with disease progression in human sarcoidosis.
RESULTS

Myeloid TSC2 deficiency promotes granuloma formation
To define the role of mTORC1 in macrophages, we generated a mouse model in which mTORC1 was constitutively active in myeloid cells by deleting its upstream inhibitor, TSC2 (ref. 17) . We crossed Tsc2 fl/fl mice 25 with transgenic mice expressing Cre under the control of the lysozyme promoter (designated Tsc2 fl/fl ,Lyz2-Cre mice). Conditional myeloid deletion of Tsc2 induced the formation of non-caseating (non-necrotizing) granulomatous aggregates, which were predominantly found in the lung and liver, as well as in the lymph nodes, of 3-month-old Tsc2 fl/fl ,Lyz2-Cre mice that were absent in control mice (Tsc2 fl/fl ) ( Fig. 1a and Supplementary Fig. 1a-c) . The hypertrophic and epithelioid cell clusters expressed the macrophage marker Mac-2 and showed strong phosphorylation of S6 (p-S6), a hallmark of mTORC1 activation (Fig. 1b) . Although the hypertrophic cells expressed some myeloperoxidase, they could be clearly distinguished from neutrophils ( Supplementary Fig. 1d ). The phenotype worsened by 6 months and was accompanied by strong inflammatory infiltrates ( Fig. 1c) . At about 4 months, Tsc2 fl/fl ,Lyz2-Cre mice developed swollen paws and tails as a result of excessive granulomas that were largely composed of hypertrophic Mac-2-and F4/80-positive macrophages ( Fig. 1d,e ). We also found marked hypertrophy in Tsc2 fl/fl ,Lyz2-Cre peritoneal macrophages ( Fig. 1f) A r t i c l e s in the lung and liver, suggesting that hypertrophic macrophage accumulation represents a cell-autonomous phenotype (Fig. 1g) .
Alveolar macrophages have a central role in human granulomatous lung lesions 8, 26 . We observed a population of hypertrophic lung cells in Tsc2 fl/fl ,Lyz2-Cre, but not Tsc2 fl/fl , mice ( Fig. 1h and Supplementary  Fig. 2a ). Phenotypic analysis using a previously established protocol 27 revealed that these cells consisted of hypertrophic alveolar macrophages, but not typical interstitial macrophages, infiltrating Ly6C hi monocytes, or other known myeloid or lymphoid immune cells ( Supplementary Fig. 2b,c) . Functional characterization of the inflamed lung showed enhanced mRNA expression of Lgals3 (encoding Mac-2), Chil3, Igf1, Il10 and Mrc1, but reduced expression of Nos2 (encoding iNOS), indicating that the macrophages had an enhanced alternative (M2-like) polarization (Fig. 1i) . The polarization profile, however, was not strongly maintained in bone-marrow-derived macrophages (BMDMs) in vitro (Supplementary Fig. 2d ). Thus, hypertrophic M2-like macrophages progressively accumulated in various tissues of Tsc2 fl/fl ,Lyz2-Cre mice in a cell-autonomous manner and formed granulomas that disturbed normal tissue homeostasis.
TSC2 prevents cluster formation and proliferation
To identify how deletion of TSC2 promotes hypertrophic granuloma formation, we generated BMDMs from Tsc2 fl/fl and Tsc2 fl/fl ,Lyz2-Cre mice. As expected Tsc2 fl/fl ,Lyz2-Cre BMDMs showed constitutive activation of the mTORC1 pathway, as indicated by phosphorylation of the downstream effector S6 and activation of the translationinitiation inhibitor 4E-BP1, which can both be blocked by rapamycin ( Fig. 2a and Supplementary Fig. 3a ). We also found that the activity of mTORC2, as indicated by phosphorylation of Akt serine 473 (p-Akt (S473)), was decreased in these cells ( Fig. 2a) . In addition, the macrophage growth factor CSF1 and lipopolysaccharide (LPS) induced phosphorylation of TSC2 on Ser939, which was accompanied by mTORC1 activation in wild-type BMDMs (Supplementary Fig. 3b ). Expression of the myeloid-specific surface markers F4/80, CD11b, CD115, Gr1 or CD11c was similar between Tsc2 fl/fl and Tsc2 fl/fl ,Lyz2-Cre macrophages, suggesting that the loss of TSC2 does not impair macrophage differentiation (Fig. 2b) . However, Tsc2 fl/fl ,Lyz2-Cre BMDMs formed granulomatous cell clusters after prolonged culture in vitro and had increased granularity and cell size ( Fig. 2c,d and Supplementary Fig. 3c,d) , reminiscent of the hypertrophic cells observed in vivo. Notably, rapamycin treatment reversed clustering as well as the hypertrophic phenotype of BMDMs and of isolated lung macrophages from Tsc2 fl/fl ,Lyz2-Cre mice ( Fig. 2c and Supplementary Fig. 3c ,e,f). Tsc2 fl/fl ,Lyz2-Cre dendritic cells or human and mouse fibroblasts, where Tsc2 was knocked down, did not show granulomatous cluster formation, indicating specificity toward the macrophage lineage ( Supplementary Fig. 3g,h) . We noticed higher numbers of Tsc2 fl/fl ,Lyz2-Cre BMDM compared with Tsc2 fl/fl cells on day 7 of culture, suggestive of enhanced proliferation ( Supplementary Fig. 4a ). Cell cycle analysis confirmed that CSF1deprived Tsc2 fl/fl ,Lyz2-Cre macrophages had enhanced cell cycling, as indicated by higher percentages of cells in the S and G2/M phase. ( Fig. 2e and Supplementary Fig. 4b ). This proliferative phenotype was also observed in Tsc2 fl/fl ,Lyz2-Cre peritoneal macrophages in vivo (Fig. 2f ). In addition, there were high numbers of Ki67-positive macrophages in the granulomatous lung and skin lesions of Tsc2 fl/fl ,Lyz2-Cre mice, indicating that macrophage proliferation contributes to the TSC2-dependent granuloma formation ( Fig. 2g and Supplementary  Fig. 4c ). Finally, the macrophage growth factor CSF1 induced much stronger mTORC1-dependent proliferation in Tsc2 fl/fl ,Lyz2-Cre macrophages than in Tsc2 fl/fl cells ( Fig. 2h and Supplementary Fig. 4d ).
These results indicate that deletion of Tsc2 in macrophages is sufficient to spontaneously induce hypertrophy, granulomatous aggregation and hyperproliferation in vitro and in vivo. 
A r t i c l e s TSC2 regulates macrophage quiescence versus inflammation
To decipher the mechanisms that contributed to this phenotype, we performed transcriptome analysis of Tsc2 fl/fl and Tsc2 fl/fl ,Lyz2-Cre macrophages deprived of CSF1. We identified 401 genes that were upregulated in Tsc2 fl/fl ,Lyz2-Cre macrophages more than twofold, whereas 426 were downregulated in these cells compared with Tsc2 fl/fl macrophages ( Fig. 3a) . Gene set enrichment analysis (GSEA) revealed that E2F transcription factor targets were the most highly enriched gene set in Tsc2 fl/fl ,Lyz2-Cre macrophages, suggesting that the TSC2-mTORC1 pathway is a major cell-cycle regulator in macrophages ( Fig. 3b,c) . We also found that E2F1 expression was slightly higher in Tsc2 fl/fl ,Lyz2-Cre BMDMs than in controls ( Supplementary  Fig. 4e ). Moreover, a proliferative self-renewal gene signature 28 was strongly enriched in Tsc2 fl/fl ,Lyz2-Cre cells (Supplementary Fig. 4f ).
In contrast, the inflammatory NF-κB response and apoptosis were augmented in Tsc2 fl/fl cells ( Fig. 3d,e ). Analysis of transcription factor binding sites corroborated that genes containing E2F binding sites were highly enriched in Tsc2 fl/fl ,Lyz2-Cre macrophages, whereas NF-κB binding sites were enriched in Tsc2 fl/fl cells (Fig. 3f) . Thus, active TSC2 limits E2F activation in macrophages, but promotes NF-κB signaling and apoptosis to balance proliferation, self-renewal and inflammatory properties.
CSF1 induces CDK4 via TSC2-mTORC1 in macrophages
Subsequently, we wanted to investigate the regulation of apoptosis and E2F activation in TSC2-deficient macrophages in more detail. Indeed, we found reduced apoptosis in CSF1-deprived Tsc2 fl/fl ,Lyz2-Cre macrophages, as shown by a rapamycin-sensitive decrease of cleaved caspase 3 (Fig. 4a) . Molecularly, this was associated with enhanced expression of the anti-apoptotic molecules Bcl-2 and survivin and with reduced protein expression of pro-apoptotic PDCD4 ( Fig. 4a and Supplementary Fig. 4g ). On the other hand, the protein expression of cyclins D1 and A, the phosphorylation of Rb and the degradation of the negative cell-cycle regulator p27 Kip1 in CSF1starved Tsc2 fl/fl ,Lyz2-Cre BMDM were indicative of active cell cycling (Supplementary Fig. 5a ). This expression pattern was reversed by rapamycin and therefore dependent on mTORC1 ( Supplementary  Fig. 5a ). D type cyclins bind to CDK4, the kinase that drives the G1-to-S transition by activating E2F 29 . There is evidence that expression of CDK4 is constitutive and not modified by environmental stimuli 30 . However, we noted enhanced protein expression of CDK4 in Tsc2 fl/fl ,Lyz2-Cre macrophages that was sensitive to mTORC1 inhibition ( Fig. 4b) . Even more notable, CSF1 stimulated CDK4 expression in Tsc2 fl/fl or C57BL/6J BMDMs in a dose-dependent manner ( Fig. 4c,  and Supplementary Fig. 5b-d) . However, CSF1 only marginally Tnfa signaling via NF-κB influenced CDK4 in Tsc2 fl/fl ,Lyz2-Cre macrophages, where CDK4 expression was already high (Fig. 4c) . CDK4 expression in the hypertrophic macrophages of the Tsc2 fl/fl ,Lyz2-Cre mice was also enhanced in vivo ( Fig. 4d and Supplementary Fig. 5e ). Furthermore, mTORC1 inhibition decreased CDK4 expression in human monocyte-derived macrophages (Supplementary Fig. 5f ). Inhibition of CDK4 activity with the CDK4/6 inhibitors PD-0332991 or SC-203873 (ref. 31 ) potently blocked cell cycling in CSF1-stimulated Tsc2 fl/fl and Tsc2 fl/fl ,Lyz2-Cre macrophages, but did not induce apoptosis in vitro ( Fig. 4e and Supplementary Fig. 5g,h) . Accordingly, PD-0332991 treatment of older Tsc2 fl/fl ,Lyz2-Cre mice that had established granulomas did not result in a marked disappearance of granulomas (data not shown). However, when we initiated granuloma formation by transplanting Tsc2 fl/fl ,Lyz2-Cre bone marrow into wild type mice, inhibition of CDK4 with PD-0332991 was able to prevent granuloma induction and formation (Fig. 4f,g) . Because inhibition of CDK4 with PD-0332991 blocked proliferation (Fig. 4e) , but did not influence CDK4 expression itself (Fig. 4h) , we reasoned that CDK4 induction by CSF1 via mTORC1 is causative for cell proliferation. Collectively, these data indicate that the mTORC1 pathway induces the expression of CDK4 following stimulation by CSF1 to drive proliferation and granuloma formation. 
A r t i c l e s TSC2 regulates metabolism via CDK4-dependent glycolysis
Cell proliferation needs to be metabolically supported and mTORC1 has been shown to be a major regulator of cellular metabolism 32 .
Because we observed the enrichment of genes involved in glycolysis and oxidative phosphorylation in TSC2-deficient macrophages (Fig. 3b) , we measured as their indicators the extracellular acidification rate (ECAR) and the oxygen consumption rate (OCR), respectively. Basal and LPS-induced ECAR and OCR were both increased in Tsc2 fl/fl ,Lyz2-Cre BMDMs compared with controls ( Fig. 5a and Supplementary Fig. 6a ), indicating that glycolysis and mitochondrial respiration were increased under chronic mTORC1 activation in macrophages. Consistent with this, mTORC1-dependent glucose uptake was significantly higher in BMDMs and in peritoneal macrophages from Tsc2 fl/fl ,Lyz2-Cre mice (Fig. 5b,c) . Absolute glucose levels were decreased in Tsc2 fl/fl ,Lyz2-Cre BMDMs and in the lung of Tsc2 fl/fl ,Lyz2-Cre animals ( Fig. 5d and Supplementary Fig. 6b) . Consistent with the higher OCR, constitutive mTORC1 activation increased mitochondrial mass in the cells (Fig. 5e,f) , an effect that was reversed by rapamycin ( Fig. 5e) . A mitochondrial stress test revealed that Tsc2 fl/fl ,Lyz2-Cre mitochondria had higher mitochondrial spare respiratory capacity (Supplementary Fig. 6c ). This high mitochondrial respiration activity was consistent with the reduced citric acid levels found in Tsc2 fl/fl ,Lyz2-Cre BMDMs ( Supplementary  Fig. 6d ). Next, we aimed to determine whether CDK4 contributes to the TSC2-dependent reprogramming of the cellular metabolism. Indeed, the CDK4 inhibitor PD-0332991 significantly inhibited ECAR in Tsc2 fl/fl ,Lyz2-Cre BMDMs (Fig. 5g) . Moreover, inhibition of CDK4 reduced CSF1-stimulated ECAR activity in Tsc2 fl/fl BMDMs, but it did not influence glycolysis in CSF1-deprived cells (Fig. 5h) , suggesting that CSF1-induced activation of CDK4 via TSC2 contributes to glycolysis in macrophages. We wanted to corroborate these metabolic results in situ by measuring the enzymatic activities of glyceraldehyde-3phosphate dehydrogenase (GAPDH), lactate dehydrogenase (LDH), isocitrate dehydrogenase (IDH) and succinate dehydrogenase (SDH) on frozen tissue sections. We found significantly more p-S6-positive macrophages with high activities for GAPDH, IDH and SDH in the lungs of Tsc2 fl/fl ,Lyz2-Cre mice than in the lungs of control animals, whereas the amount of cells with high LDH activity was similar ( Fig. 5i,j) . We also observed more p-S6-positive macrophages with high GAPDH activity in the livers of Tsc2 fl/fl ,Lyz2-Cre mice (Supplementary Fig. 6e,f) . To identify the cellular functions that are fueled by the enhanced glucose metabolism in Tsc2 fl/fl ,Lyz2-Cre macrophages, we inhibited glycolysis with 2-deoxy-D-glucose (2-DG). 2-DG at doses of only 0.25 mM inhibited proliferation of CSF1stimulated Tsc2 fl/fl ,Lyz2-Cre and Tsc2 fl/fl BMDMs (Fig. 5k,l) . Notably, 2-DG induced cleavage of caspase-3 in CSF1-deprived Tsc2 fl/fl and in Tsc2 fl/fl ,Lyz2-Cre BMDMs, but was unable to do so in CSF1-stimulated macrophages (Fig. 5m) . These results indicate that deletion of TSC2 rewires the metabolism of macrophages toward increased CDK4-dependent glycolysis and mitochondrial respiration that is critical for proliferation, but also inhibits apoptosis under growthfactor-deprived conditions.
Granulomas in human sarcoidosis show active mTORC1 signaling
Our observations in Tsc2 fl/fl ,Lyz2-Cre mice most strongly resemble the histological phenotype of patients with sarcoidosis; for example, alveolar-like epithelioid macrophages that accumulate in the interstitium and express high levels of Lgals3. This prompted us to analyze whether mTORC1 activation is found in biopsies of sarcoidosis patients. We noticed activated mTORC1 signaling in granulomatous lesions in 33% A r t i c l e s of 27 biopsies in an initial screening ( Fig. 6a) , with the hypertrophic cells also expressing Mac-2 ( Fig. 6b) . To substantiate these findings, we reanalyzed a published clinical study, which compared active but self-limiting with active but progressive sarcoidosis in 15 patients 9 . We performed GSEA for hallmark gene sets and found that the mTORC1 pathway was significantly enriched (FDR < 0.001) in the progressive set ( Fig. 6c ). E2F targets (FDR < 0.001) and a glycolysis gene set (FDR < 0.036) were also enriched in this patient population, suggesting that macrophage proliferation and glycolysis contribute to the severity of the disease (Fig. 6c) . Although TSC2 was expressed at comparable levels, mRNA expression of TSC1 was significantly decreased (P < 0.05) in patients with the progressive relative to the self-limiting form of the disease (Supplementary Fig. 7) . Notably, the gene set that was differentially expressed between the self-limiting and the progressive disease separated Tsc2 fl/fl and Tsc2 fl/fl ,Lyz2-Cre BMDMs in an unsupervised cluster analysis of the mRNA gene expression data (Fig. 6d) . Moreover, we detected active cell proliferation inside the granulomas in 44% of 27 human sarcoidosis patients (Fig. 6e,f) . A positive association (P = 0.003) of p-S6 and Ki67 in the granulomas of these patients confirmed the importance of that finding (Fig. 6g) . Taken together, these results suggest that mTORC1-dependent macrophage proliferation and glycolysis contribute to disease progression in sarcoidosis.
mTORC1 inhibition resolves granulomas in mice
The link between mTORC1 and sarcoidosis progression encouraged us to study whether the granuloma phenotype in Tsc2 fl/fl ,Lyz2-Cre mice depends on constitutive mTORC1 activation. After a treatment period of 3 weeks with the mTORC1 inhibitor everolimus 33 , the granulomas completely resolved in 8-week-old and 20 week-old Tsc2 fl/fl ,Lyz2-Cre mice and we observed a normal lung architecture, whereas granulomas were well visible in placebo-treated Tsc2 fl/fl ,Lyz2-Cre mice (Fig. 7a,b) . Moreover, the swelling of the extremities also disappeared following 2 weeks of mTORC1 inhibition in the old mice in vivo (Fig. 7c,d) . Mechanistically, the hypertrophic macrophages downregulated S6 phosphorylation and underwent rapid apoptosis by 2 d after everolimus treatment (Fig. 7e) . These results led us to conclude that the development and maintenance of granulomas initiated by hypertrophic macrophages in Tsc2 fl/fl ,Lyz2-Cre mice depends on the constitutive activation of mTORC1 and its inhibition restores normal tissue homeostasis in these mice.
DISCUSSION
We propose that mTORC1 is a critical rheostat that negatively regulates macrophage quiescence, whereas its constitutive activation is sufficient to initiate granuloma formation in various tissues of mice. Moreover, our data indicate that activation of mTORC1 and macrophage proliferation determines the switch from a self-limiting to a progressive form in the human granulomatous disease sarcoidosis. The induction and maintenance of granulomas remains poorly understood despite their importance for modifying disease pathology 11 . For example, excessive granuloma formation can be detrimental in non-infectious granulomatous disorders such sarcoidosis or Crohn's disease, but can also favor pathogen growth and survival in tuberculosis and schistosomiasis 3, 11 . Although we understand the morphological sequence of events during granuloma formation 1, 3 , molecular knowledge about signaling pathways that transform macrophages into hypertrophic, epithelioid macrophages that induce granulomas is virtually nonexistent. Unexpectedly, we found that activation of mTORC1 by myeloid-specific deletion of Tsc2 was sufficient to initiate and maintain granulomas by enhancing macrophage proliferation and inhibition of apoptosis in vivo. Notably, activation of mTORC1 already promoted the transformation of BMDMs into hyperproliferative and hypertrophic epithelioid cells that formed granulomatous structures in vitro. These results suggest that granuloma formation is an intrinsic feature of macrophages. Currently, a unifying theory is missing from the explanation of why diverse pathogens, cytokines, non-degradable particles and genetic disorders initiate the formation of granulomas. Our results suggest a model in which the inability to clear a stimulus initiates and maintains mTORC1 activity to induce cell hypertrophy and granuloma formation. Thus, Tsc2 fl/fl ,Lyz2-Cre mice present a potentially useful tool for studying the molecular principles of granuloma formation in non-infectious and infectious diseases in vivo, and allow the dissection of cell-intrinsic pathways necessary for granuloma initiation from pathogenic signals that modify granuloma organization.
Macrophage proliferation has already been described in sarcoidosis and other human granulomatous diseases 34, 35 . Moreover, macrophages also proliferate in experimental granulomatous models 36, 37 ; however, the contribution of macrophage proliferation itself to granuloma formation has not been investigated mechanistically.
Our data indicate that mTORC1-dependent macrophage proliferation contributes mainly to the establishment of the granulomatous phenotype in Tsc2 fl/fl ,Lyz2-Cre mice. There is a renewed interest in defining the mechanisms of macrophage proliferation in vivo during pathologies such as atherosclerosis or obesity and under steady-state conditions to maintain the macrophage pool in tissues [38] [39] [40] . Our gene expression analysis in BMDMs suggests that cell-cycle progression and E2F transcription factors are the main targets of TSC2-mTORC1 in macrophages, a finding that was unexpected despite the knowledge of the role of mTORC1 in cell proliferation in other cells 41, 42 . An important finding from our study is that CDK4 expression was induced by the growth factor CSF1 via TSC2-mTORC1 to promote macrophage proliferation. It is currently believed that CDKs remain largely constant throughout the cell cycle 30 ; however, we found that the cell cycle was not only controlled by the amount of cyclins, but also by the expression of a CDK. It can be speculated that the presence of adequate amounts of CDKs such as CDK4 is rate limiting in addition to sufficient amounts of cyclins. Consistent with this suggestion, transgenic expression of CDK4 in the epidermis is sufficient to drive cell-cycle progression as well as hypertrophy 43 , similar to our findings in Tsc2 fl/fl ,Lyz2-Cre mice. Moreover, alveolar macrophages, which possess a high self-renewal proliferative capacity, also express high levels of CDK4. Although we found enhanced proliferation, we also observed the upregulation of survival genes and decreased apoptosis in BMDMs in vitro and in Tsc2 fl/fl ,Lyz2-Cre mice in vivo. This contributed to the maintenance of the granulomas, as inhibition of mTORC1 for 2 d readily induced apoptosis in the macrophages in vivo and completely resolved the granulomas. Thus, TSC2 and mTORC1 maintain a balance between proliferation and apoptosis that is important for macrophage tissue homeostasis. Transitions between quiescent and activated or proliferating states require the reprogramming of the cellular metabolism to support these functional changes 44, 45 . We observed a prominent remodeling of the cellular metabolism toward increased glycolysis and oxidative phosphorylation in Tsc2 fl/fl ,Lyz2-Cre macrophages by enhancing GAPDH, IDH and SDH activities that supported macrophage proliferation. Limiting the glycolytic flux radically suppressed cell cycling and proliferation, corroborating the important role of glucose as a carbon source for macrophages 45 . Our findings describe a previously unknown role for mTORC1 in the regulation of the cellular metabolism 21 and indicate that CDK4 contributes to mTORC1-dependent glycolysis to fuel proliferation.
Sarcoidosis onset is gradual, from an asymptomatic state to a progressive disease that can become life threatening 9 . Notably, a genome-wide association study identified 12q13.3-q14.1 as a risk locus for sarcoidosis that induces overexpression of eight genes, including CDK4 in four different populations 46 , and both macrophage proliferation and decreased apoptosis have been observed in sarcoidosis 35 . Moreover, sarcoid granulomas are known to have a high uptake capacity for glucose 47 , strengthening the observed association of mTORC1 activation and glycolysis with sarcoidosis progression. Although we found decreased expression of TSC1 in progressive sarcoidosis patients, the underlying reason as to why these patients have active mTORC1 signaling, as our results suggest, is currently unclear. Somatic mutations affecting the mTOR pathway or environmental triggers that the immune system is unable to clear could both promote mTORC1 activation to drive sarcoidosis progression. Hypercalcemia is diagnosed in about 5-10% of the patients; however, blood calcium levels were similar in 11-week-old Tsc2 fl/fl and Tsc2 fl/fl ,Lyz2-Cre mice (data not shown). For treatment of sarcoidosis, corticosteroids are usually recommended, but they are associated with notable side effects 5, 7 . Moreover, some patients are refractory to treatment and there is a significant rate of relapse 5, 48 . Our findings point to the evaluation of mTOR inhibitors in this patient group. Indeed, successful treatment of a sarcoidosis patient with the mTOR inhibitor rapamycin has been reported 49 . Finally, our results warrant the assessment of whether mTORC1-dependent macrophage proliferation and granuloma formation contribute to disease outcomes in other non-infectious and infectious granulomatous diseases.
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